Bayer Pharma Aktiengesellschaft

Bayer Schering Pharma Ag

Bayer Intellectual Property Gmbh

Schering Aktiengesellschaft

Deutsches Krebsforschungszentrum

Bayer Aktiengesellschaft

Ludwig Zorn

Philip Lienau

Ulf Bömer

Knut Eis

Rolf Bohlmann

Arne Scholz

Detlev Sülzle

Volker Schulze

Judith Günther

Andrea Hägebarth

Gerhard Siemeister

Dirk Kosemund

Ulrich Lücking

Benjamin Bader

Johannes Platzek

Andreas Huth

Martin Haberey

Mark Jean Gnoth

Andreas Menrad

Karl-Heinrich Fritzemeier

Norbert Schmees

Werner Skuballa

Hanns-Joachim Weinmann

Gerhard Sauer

Bernd Buchmann

Karl-Heinz Thierauch

Orlin Petrov

Martin Kruger

Christa Hegele-Hartung

Rosemarie Lichtner

Hartmut Rehwinkel

Heribert Schmitt-Willich

Helmut Hofmeister

William Johnston Scott

Katja Zimmermann

Kai Thede

Rolf Jautelat

Joachim Kuhnke

Antje Margret Wengner

Duy Nguyen

Yukishige Nishino

Sven Ring

Florian Puehler

Kirstin Petersen

Detlef Stöckigt

Michael Platten

Lars Röse

Ulrike Röhn

Niels Böhnke

Ilona Gutcher

Holger Hess-Stumpp

Stuart Ince

Bernd Misselwitz

Nikolaus Heinrich

Martin Krueger

Hermann Kuenzer

Julien Lefranc

Heiko Schirmer

Jorg Kroll

Florian Pühler

Karl H Thierauch

Daniel Korr

Jörg Fanghänel

Rafael Carretero

Christina Kober

Stuat Ince

Martin Schneider

Roland Neuhaus

Ursula Mönning

Thomas Brumby

Ingo Hartung

Ningshu Liu

Stefan Golz

Jens Hoffmann

Jens Nagel

Olaf Panknin

Olaf Peters

Hans-Peter Muhn

Marion Hitchcock

Nico Bräuer

Stefan Kaulfuss

Thorsten Blume

Karsten Parczyk

Dirk Schneider

Antonius Ter Laak

Reinhard Nubbemeyer

Detlev Suelzle

Monika Lessl

Eckhard Bender

Steffen Borden

Horst Irlbacher

Katja Prelle

Hermann Kunzer

Manfred Möwes

Franziska Siegel

Anja Richter

Uwe Kollenkirchen

Norbert Gallus

Gernot Langer

Daniel Basting

The present invention covers 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyri-dazine-4-carboxamide compounds of general formula (I): in which R, R, R, R, R, X, Y and Z are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients. 

3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides

The present invention covers 2-phenylpyrimidine-4-carboxamide compounds of general formula (I): (I) 5 in which X, Y, Z, R1, R2, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients. 

2-phenylpyrimidine-4-carboxamides as AHR inhibitors

Disclosed are compounds of general formula (I): wherein R, R, A, X, Y and Z are as defined herein, methods of preparing the compounds, intermediate compounds useful for preparing the compounds, pharmaceutical compositions and combinations comprising the compounds and the use of the compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.

Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides

The present invention covers 2-hetarylpyrimidine-4-carboxamide compounds of general formula (I): in which X, Y, Z, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients. 

2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists

The present invention covers 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients. 

3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides

The present invention relates to compounds of general formula (I): in which R, R, R, R, R, R, R, R, R, R, R, Rand X are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

Fused imidazoles as mIDH1 inhibitors

The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I): in which A, E, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders

The present invention relates to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease such as cancer, wherein i.a.: Lrepresents an optionally substituted methylene or ethylene group; Lrepresents &#x2014;N(H)&#x2014;C(&#x2550;O)&#x2014; or &#x2014;C(&#x2550;O)&#x2014;N(H)&#x2014;; Rrepresents an optionally substituted 5- to 8-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, aryl, heteroaryl or &#x2014;N(R7)(Ci-C6-alkyl) group; Rrepresents an optionally substituted 5- or 6-membered heteroaryl group; Rrepresents an optionally substituted phenyl group. 

Compounds

The present invention relates to 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group

The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I), in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Aminoimidazopyridazines

The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I), in which A, R1, R2, R3, R4, R5 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Amino-substituted imidazopyridazines

The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I): in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Amidoimidazopyridazines as MKNK-1 kinase inhibitors

The present invention relates to substituted aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Substituted aminoimidazopyridazines

The present invention relates to novel benzimidazole derivatives of the general formula processes for their preparation and their use for the production of pharmaceutical compositions for the treatment of diseases and indications that are connected with the receptor EP4.

Benzimidazole derivatives as EP4 antagonists

The present invention relates to N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group

Growing community of inventors

Berlin, Germany

Ludwig Zorn